-- Baijin Life Science (HKG:1466) granted over 67.9 million share options to various directors and employees under a 2024 incentive scheme, according to a Friday Hong Kong bourse filing.
The options are exercisable into an equal number of ordinary shares in the firm's share capital for five years at HK$0.54 apiece.
The options are not subject to performance targets.
The jewelry maker now has no shares available for future grant under the scheme.